Patents by Inventor Qixiao Zhai
Qixiao Zhai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12364722Abstract: The present disclosure discloses multifunctional lactobacilli capable of relieving a toxic effect of perfluorooctanoic acid (PFOA) and use thereof, and belongs to the technical field of microorganisms.Type: GrantFiled: December 27, 2021Date of Patent: July 22, 2025Assignee: Jiangnan UniversityInventors: Gang Wang, Wei Chen, Jianxin Zhao, Hao Zhang, Xi Liang, Qingmin Kong, Qixiao Zhai, Wenwei Lu, Shumao Cui, Bo Yang, Bingyong Mao
-
Patent number: 12285448Abstract: Described is a B. breve strain for relieving rheumatoid arthritis and application thereof, belonging to the technical field of microorganisms. Described is a B. breve strain CCFM1078 possessing the effect of relieving rheumatoid arthritis, and shown to: promote secretion of anti-inflammatory factor IL-10 from RAW264.7 cells; reduce joint thickness, clinical score, and incidence of rats with rheumatoid arthritis; decrease levels of the pro-inflammatory cytokines TNF? and IL-1? in the serum of rats with rheumatoid arthritis; regulate the content of short-chain fatty acids in the feces of rats with rheumatoid arthritis; decrease the proportion of Th17 cells in the mesenteric lymph nodes of rats with rheumatoid arthritis; and reduce secretion of pro-inflammatory factor IL-6 from synovial cells.Type: GrantFiled: March 17, 2022Date of Patent: April 29, 2025Inventors: Bo Yang, Wei Chen, Zhexin Fan, Qixiao Zhai, Gang Wang, Wenwei Lu, Shumao Cui, Jianxin Zhao, Hao Zhang
-
Patent number: 12280079Abstract: The disclosure discloses a strain of Lactobacillus crispatus capable of preventing and/or treating Helicobacter pylori infection, and belongs to the technical fields of microorganisms and medicine. The disclosure provides a strain of Lactobacillus crispatus CCFM1118. The Lactobacillus crispatus CCFM1118 can inhibit Helicobacter pylori, specifically embodied in that: (1) the diameter of an inhibition zone of supernatant of the Lactobacillus crispatus CCFM1118 on Helicobacter pylori can reach 13.14 mm; and (2) the Lactobacillus crispatus CCFM1118 can significantly reduce the adhesion of Helicobacter pylori to AGS cells. Therefore, the Lactobacillus crispatus CCFM1118 has great application prospects in inhibiting Helicobacter pylori (not for the purposes of disease diagnosis and treatment) and preparing Helicobacter pylori inhibitors.Type: GrantFiled: March 31, 2022Date of Patent: April 22, 2025Assignee: Jiangnan UniversityInventors: Qixiao Zhai, Wei Chen, Meiyi Zhang, Leilei Yu, Fengwei Tian, Shunhe Wang, Jianxin Zhao, Hao Zhang
-
Patent number: 12280077Abstract: The disclosure discloses Bifidobacterium longum with the ability to relieve atopic dermatitis and its application, and belongs to the technical fields of microorganisms and medicine. The Bifidobacterium longum of the disclosure has the effects of relieving atopic dermatitis, and the effects are specifically embodied in: (1) significantly improving the degree of ear swelling in mice with atopic dermatitis; (2) significantly improving skin pathological symptoms and inflammatory cell infiltration in mice with atopic dermatitis; (3) significantly reducing the serum IgE level in mice with atopic dermatitis; (4) significantly reducing the levels of IL-4 and IL-13 in the skin tissues of mice with atopic dermatitis; and (5) significantly reducing the level of histamine in the skin tissues of mice with atopic dermatitis. Therefore, the Bifidobacterium longum has great application prospects in the preparation of products for the prevention and/or treatment of atopic dermatitis.Type: GrantFiled: May 20, 2021Date of Patent: April 22, 2025Assignee: Jiangnan UniversityInventors: Jianxin Zhao, Wenwei Lu, Wei Chen, Zhifeng Fang, Qixiao Zhai, Bo Yang, Hao Zhang
-
Patent number: 12275934Abstract: The disclosure discloses a strain of Lactobacillus rhamnosus and application thereof in inhibiting Helicobacter pylori, and belongs to the technical fields of microorganisms and medicine. The disclosure provides a strain of Lactobacillus rhamnosus CCFM1119. The Lactobacillus rhamnosus CCFM1119 can prevent and/or treat Helicobacter pylori infection, specifically embodied in that: (1) the Lactobacillus rhamnosus CCFM1119 can significantly relieve the gastrointestinal symptoms of patients with Helicobacter pylori infection; (2) the Lactobacillus rhamnosus CCFM1119 can significantly reduce the amount of colonization of Helicobacter pylori in patients with Helicobacter pylori infection; and (3) the Lactobacillus rhamnosus CCFM1119 can significantly increase the clearance rate of Helicobacter pylori in patients with Helicobacter pylori infection.Type: GrantFiled: April 1, 2022Date of Patent: April 15, 2025Assignee: Jiangnan UniversityInventors: Qixiao Zhai, Wei Chen, Jianxin Zhao, Meiyi Zhang, Shumao Cui, Wenwei Lu, Fengwei Tian, Leilei Yu, Gang Wang, Hao Zhang
-
Publication number: 20230346856Abstract: The disclosure discloses a strain of Bifidobacterium breve capable of preventing and relieving psoriasis and application thereof, belonging to the field of microbial technologies and medical technologies. The disclosure provides new uses of B. breve CCFM1078 in inhibiting the release of IL-23/Th17 axis related inflammatory factors, and relieving the psoriasis. The B. breve CCFM1078 of the disclosure can relieve the lesion skin of psoriasis-like mice, and can inhibit thickening of the skin epidermal layer, so that the IL-23 level, the IL-22 level and the IL-17 level in the skin decrease by 20.3%, 22.0% and 18.3%, respectively. The B. breve CCFM1078 has a great application prospect in the preparation of a product (such as a food, a drug or a health food) for preventing and/or treating psoriasis.Type: ApplicationFiled: June 21, 2023Publication date: November 2, 2023Inventors: Wei CHEN, Wenwei LU, Yadan DENG, Qixiao ZHAI, Bo YANG, Shumao CUI, Bingyong MAO, Hongchao WANG, Jianxin ZHAO, Hao ZHANG
-
Publication number: 20230263844Abstract: The disclosure relates to Bifidobacterium longum for preventing and/or treating essential hypertension, and belongs to the technical fields of microorganisms and medicine. The B. longum CCFM752 provided by the disclosure prevents essential hypertension, specifically including: (1) significantly decreasing the O2- level, the H2O2 level and the NADPH oxidase activity in A7R5 cells stimulated with Angiotensin II; (2) significantly increasing the CAT activity in A7R5 cells, aortas of SHRs and serum of SHRs; (3) significantly decreasing the blood pressure level of SHRs; (4) significantly decreasing the aortic wall ROS level, the aortic wall NADPH oxidase activity, the aortic wall collagen level and the aortic wall thickness index of SHRs; and (5) significantly increasing the aortic wall eNOS activity of SHRs. It can be seen that the B. longum CCFM752 has great application prospects in preparation of products (such as food or drugs) for preventing and/or treating hypertension.Type: ApplicationFiled: March 29, 2023Publication date: August 24, 2023Inventors: Wenwei Lu, Wei Chen, Yusheng Wang, Qixiao Zhai, Jianxin Zhao, Hao Zhang
-
Patent number: 11628192Abstract: The disclosure discloses Bacteroides fragilis for relieving endotoxin infection and application thereof, and belongs to the technical field of microorganisms. The Bacteroides fragilis CCFM1020 of the disclosure has low immunogenicity, and can reduce the content of pro-inflammatory factors and increase the concentration of anti-inflammatory factors in the blood of hosts infected with endotoxin, up-regulate the number of Foxp3+ regulatory T cells and stabilize the composition of the intestinal microbiota. A pharmaceutical composition of the Bacteroides fragilis CCFM1020 for relieving endotoxin infection has broad application prospects.Type: GrantFiled: October 28, 2020Date of Patent: April 18, 2023Assignee: JIANGNAN UNIVERSITYInventors: Qixiao Zhai, Wei Chen, Huizi Tan, Wenwei Lu, Fengwei Tian, Jianxin Zhao, Hao Zhang
-
Patent number: 11419905Abstract: The disclosure discloses Bacteroides ovatus for relieving endotoxin infection and application thereof, and belongs to the technical field of microorganisms. The Bacteroides ovatus CCFM1021 of the disclosure has low immunogenicity, and can reduce the content of pro-inflammatory factors and increase the concentration of anti-inflammatory factors in the blood of mice infected with endotoxin, up-regulate the number of Foxp3+ regulatory T cells and stabilize the composition of the intestinal microbiota. A pharmaceutical composition of the Bacteroides ovatus CCFM1021 for relieving endotoxin infection has broad application prospects.Type: GrantFiled: October 28, 2020Date of Patent: August 23, 2022Assignee: Jiangnan UniversityInventors: Wei Chen, Qixiao Zhai, Huizi Tan, Wenwei Lu, Fengwei Tian, Jianxin Zhao, Hao Zhang
-
Publication number: 20220228106Abstract: The disclosure discloses a strain of Lactobacillus rhamnosus and application thereof in inhibiting Helicobacter pylori, and belongs to the technical fields of microorganisms and medicine. The disclosure provides a strain of Lactobacillus rhamnosus CCFM1119. The Lactobacillus rhamnosus CCFM1119 can prevent and/or treat Helicobacter pylori infection, specifically embodied in that: (1) the Lactobacillus rhamnosus CCFM1119 can significantly relieve the gastrointestinal symptoms of patients with Helicobacter pylori infection; (2) the Lactobacillus rhamnosus CCFM1119 can significantly reduce the amount of colonization of Helicobacter pylori in patients with Helicobacter pylori infection; and (3) the Lactobacillus rhamnosus CCFM1119 can significantly increase the clearance rate of Helicobacter pylori in patients with Helicobacter pylori infection.Type: ApplicationFiled: April 1, 2022Publication date: July 21, 2022Inventors: Qixiao ZHAI, Wei CHEN, Jianxin ZHAO, Meiyi ZHANG, Shumao CUI, Wenwei LU, Fengwei TIAN, Leilei YU, Gang WANG, Hao ZHANG
-
Publication number: 20220218769Abstract: The disclosure discloses a strain of Lactobacillus crispatus capable of preventing and/or treating Helicobacter pylori infection, and belongs to the technical fields of microorganisms and medicine. The disclosure provides a strain of Lactobacillus crispatus CCFM1118. The Lactobacillus crispatus CCFM1118 can inhibit Helicobacter pylori, specifically embodied in that: (1) the diameter of an inhibition zone of supernatant of the Lactobacillus crispatus CCFM1118 on Helicobacter pylori can reach 13.14 mm; and (2) the Lactobacillus crispatus CCFM1118 can significantly reduce the adhesion of Helicobacter pylori to AGS cells. Therefore, the Lactobacillus crispatus CCFM1118 has great application prospects in inhibiting Helicobacter pylori (not for the purposes of disease diagnosis and treatment) and preparing Helicobacter pylori inhibitors.Type: ApplicationFiled: March 31, 2022Publication date: July 14, 2022Inventors: Qixiao ZHAI, Wei CHEN, Meiyi ZHANG, Leilei YU, Fengwei TIAN, Shunhe WANG, Jianxin ZHAO, Hao ZHANG
-
Publication number: 20220211776Abstract: The disclosure discloses a B. breve strain capable of relieving rheumatoid arthritis and application thereof, and belongs to the technical field of microorganisms. The disclosure screens out a B. breve strain CCFM1078, and the B. breve CCFM1078 has the effect of relieving rheumatoid arthritis, being specifically embodied in: significantly promoting secretion of anti-inflammatory factor IL-10 from RAW264.7 cells; significantly reducing the joint thickness, clinical score and incidence of rats with rheumatoid arthritis; significantly decreasing the levels of pro-inflammatory cytokines TNF? and IL-1? in the serum of rats with rheumatoid arthritis; significantly regulating the content of short-chain fatty acids in the feces of rats with rheumatoid arthritis; significantly decreasing the proportion of Th17 cells in the mesenteric lymph nodes of rats with rheumatoid arthritis; and significantly reducing secretion of pro-inflammatory factor IL-6 from synovial cells.Type: ApplicationFiled: March 17, 2022Publication date: July 7, 2022Inventors: Bo YANG, Wei CHEN, Zhexin FAN, Qixiao ZHAI, Gang WANG, Wenwei LU, Shumao CUI, Jianxin ZHAO, Hao ZHANG
-
Patent number: 11369648Abstract: The disclosure discloses a probiotic mixed preparation with anti-influenza ability and application thereof, and belongs to the technical fields of microorganisms and medicines. The probiotic mixed preparation has anti-influenza effects, which are embodied in: (1) significantly reducing the degree of weight loss of influenza mice; (2) significantly improving the blood indexes of the influenza mice; (3) significantly improving the inflammation status of respiratory tract infections in the influenza mice; (4) significantly reducing the viral load in the lungs of the influenza mice (i.e., significantly inhibiting the replication and multiplication of influenza viruses in the influenza mice); and (5) significantly increasing the expression quantity of antiviral protein MxA in the lungs of the influenza mice. Therefore, the probiotic mixed preparation has great application prospects in preparation of a product for preventing and/or treating atopic dermatitis and even preventing and/or treating influenza.Type: GrantFiled: June 4, 2020Date of Patent: June 28, 2022Assignee: JIANGNAN UNIVERSITYInventors: Wei Chen, Wenwei Lu, Qixiao Zhai, Xinyang Liu, Jianxin Zhao, Feng Hang, Hao Zhang
-
Publication number: 20220152130Abstract: The present disclosure discloses multifunctional lactobacilli capable of relieving a toxic effect of perfluorooctanoic acid (PFOA) and use thereof, and belongs to the technical field of microorganisms.Type: ApplicationFiled: December 27, 2021Publication date: May 19, 2022Inventors: Gang WANG, Wei CHEN, Jianxin ZHAO, Hao ZHANG, Xi LIANG, Qingmin KONG, Qixiao ZHAI, Wenwei LU, Shumao CUI, Bo YANG, Bingyong MAO
-
Publication number: 20210268043Abstract: The disclosure discloses Bifidobacterium longum with the ability to relieve atopic dermatitis and its application, and belongs to the technical fields of microorganisms and medicine. The Bifidobacterium longum of the disclosure has the effects of relieving atopic dermatitis, and the effects are specifically embodied in: (1) significantly improving the degree of ear swelling in mice with atopic dermatitis; (2) significantly improving skin pathological symptoms and inflammatory cell infiltration in mice with atopic dermatitis; (3) significantly reducing the serum IgE level in mice with atopic dermatitis; (4) significantly reducing the levels of IL-4 and IL-13 in the skin tissues of mice with atopic dermatitis; and (5) significantly reducing the level of histamine in the skin tissues of mice with atopic dermatitis. Therefore, the Bifidobacterium longum has great application prospects in the preparation of products for the prevention and/or treatment of atopic dermatitis.Type: ApplicationFiled: May 20, 2021Publication date: September 2, 2021Inventors: Jianxin ZHAO, Wenwei LU, Wei CHEN, Zhifeng FANG, Qixiao ZHAI, Bo YANG, Hao ZHANG
-
Publication number: 20210060091Abstract: The disclosure discloses Bacteroides ovatus for relieving endotoxin infection and application thereof, and belongs to the technical field of microorganisms. The Bacteroides ovatus CCFM1021 of the disclosure has low immunogenicity, and can reduce the content of pro-inflammatory factors and increase the concentration of anti-inflammatory factors in the blood of mice infected with endotoxin, up-regulate the number of Foxp3+ regulatory T cells and stabilize the composition of the intestinal microbiota. A pharmaceutical composition of the Bacteroides ovatus CCFM1021 for relieving endotoxin infection has broad application prospects.Type: ApplicationFiled: October 28, 2020Publication date: March 4, 2021Inventors: Wei CHEN, Qixiao ZHAI, Huizi TAN, Wenwei LU, Fengwei TIAN, Jianxin ZHAO, Hao ZHANG
-
Publication number: 20210038655Abstract: The disclosure discloses Bacteroides fragilis for relieving endotoxin infection and application thereof, and belongs to the technical field of microorganisms. The Bacteroides fragilis CCFM1020 of the disclosure has low immunogenicity, and can reduce the content of pro-inflammatory factors and increase the concentration of anti-inflammatory factors in the blood of hosts infected with endotoxin, up-regulate the number of Foxp3+ regulatory T cells and stabilize the composition of the intestinal microbiota. A pharmaceutical composition of the Bacteroides fragilis CCFM1020 for relieving endotoxin infection has broad application prospects.Type: ApplicationFiled: October 28, 2020Publication date: February 11, 2021Inventors: Qixiao ZHAI, Wei CHEN, Huizi TAN, Wenwei LU, Fengwei TIAN, Jianxin ZHAO, Hao ZHANG
-
Publication number: 20200368297Abstract: The disclosure discloses a probiotic mixed preparation with anti-influenza ability and application thereof, and belongs to the technical fields of microorganisms and medicines. The probiotic mixed preparation has anti-influenza effects, which are embodied in: (1) significantly reducing the degree of weight loss of influenza mice; (2) significantly improving the blood indexes of the influenza mice; (3) significantly improving the inflammation status of respiratory tract infections in the influenza mice; (4) significantly reducing the viral load in the lungs of the influenza mice (i.e., significantly inhibiting the replication and multiplication of influenza viruses in the influenza mice); and (5) significantly increasing the expression quantity of antiviral protein MxA in the lungs of the influenza mice. Therefore, the probiotic mixed preparation has great application prospects in preparation of a product for preventing and/or treating atopic dermatitis and even preventing and/or treating influenza.Type: ApplicationFiled: June 4, 2020Publication date: November 26, 2020Inventors: Wei CHEN, Wenwei LU, Qixiao ZHAI, Xinyang LIU, Jianxin ZHAO, Feng HANG, Hao ZHANG
-
Patent number: 9451781Abstract: The invention provides a novel strain of cadmium-removing Lactobacillus plantarum bacterium, CCFM8610, which has a good tolerance to acidic environments. Lactobacillus plantarum CCFM8610 has a good tolerance to cadmium-containing medium and can effectively bind cadmium in vitro. Animal studies have shown that it can effectively reduce tissue cadmium accumulation and facilitate fecal cadmium excretion. Lactobacillus plantarum CCFM8610 has a great potential to be used as an active ingredient in cadmium-removing pharmaceutical drugs and fermented foods.Type: GrantFiled: December 7, 2012Date of Patent: September 27, 2016Assignee: Jiangnan UniversityInventors: Wei Chen, Fengwei Tian, Qixiao Zhai, Gang Wang, Xiaoming Liu, Qiuxiang Zhang, Daming Fan, Jianxin Zhao, Hao Zhang
-
Patent number: 9320766Abstract: The Lactobacillus plantarum CCFM8661 is tolerant to acid and lead ions in vitro which can tolerate lead ions solution with the initial concentration of 150 mg/L, and has a strong capability of binding lead ions, which can reduce the lead level in mice blood, liver, kidney and stomach, significantly improve antioxidant indicators and alleviate pathological symptoms of lead exposed mice.Type: GrantFiled: July 18, 2012Date of Patent: April 26, 2016Assignee: Jiangnan UniversityInventors: Fengwei Tian, Wei Chen, Qixiao Zhai, Hao Zhang, Jianxin Zhao, Gang Wang, Yuanda Song, Qiuxiang Zhang, Xiaoming Liu, Min Guo, Daming Fan